Axsome Therapeutics Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 11.1% | 11.4% | 9.4% | 8.0% | 9.8% | 11.3% | 10.3% | 8.4% | 9.2% | 8.1% | 8.9% | 8.1% | 9.0% | 7.0% | 6.3% | 7.7% | 6.2% | 6.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 88.9% | 88.6% | 90.6% | 92.0% | 90.2% | 88.7% | 89.7% | 91.6% | 90.8% | 91.9% | 91.1% | 91.9% | 91.0% | 93.0% | 93.7% | 92.3% | 93.8% | 93.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 179.0% | 88.3% | 60.3% | 18.8% | 44.1% | 49.8% | 43.1% | 49.1% | 57.2% | 43.3% | 46.3% | 36.9% | 33.0% | 23.5% | 24.9% | 27.6% | 21.2% | 24.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 353.3% | 242.7% | 401.1% | 55.8% | 111.9% | 95.3% | 87.7% | 100.0% | 84.0% | 91.2% | 73.3% | 99.4% | 62.8% | 63.6% | 86.4% | 96.8% | 95.3% | 86.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 533.1% | 340.3% | 336.4% | 98.8% | 229.5% | 196.2% | 227.1% | 181.3% | 180.3% | 151.7% | 152.3% | 138.9% | 115.5% | 120.0% | 108.7% | 125.4% | 116.5% | 117.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -444.2% | -251.8% | -245.8% | -6.7% | -139.3% | -107.5% | -137.4% | -89.7% | -89.5% | -59.8% | -61.1% | -46.9% | -24.5% | -27.0% | -15.0% | -33.1% | -22.7% | -24.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 25.6% | 14.3% | 5.4% | 2.4% | 5.8% | 1.3% | 1.0% | 1.4% | 1.5% | 1.9% | 1.9% | 2.0% | 1.2% | 0.7% | 0.6% | 0.6% | 0.7% | 0.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -469.8% | -266.1% | -251.3% | -9.1% | -145.2% | -108.8% | -138.4% | -91.1% | -91.0% | -61.7% | -63.0% | -48.9% | -32.6% | -27.6% | -14.4% | -33.8% | -23.4% | -24.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 15.8% | 14.3% | 22.7% | 2.7% | -1.3% | -1.2% | -0.5% | 0.0% | – | – | 0.1% | – | -0.6% | – | 0.2% | – | 0.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -469.8% | -266.1% | -251.3% | -11.9% | -143.8% | -107.6% | -137.9% | -91.1% | -91.0% | -61.7% | -63.1% | -48.9% | -32.0% | -27.6% | -14.6% | -33.8% | -23.5% | -24.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -439.8% | -241.8% | -237.6% | -5.0% | -134.7% | -104.5% | -135.0% | -87.3% | -87.3% | -57.8% | -59.4% | -45.2% | -28.4% | -26.0% | -12.6% | -31.9% | -22.7% | -23.2% |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.